Health
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) capsules and AUSTEDO XR (deutetrabenazine) at therapeutic doses. Results from the study confirmed that both compounds engage VMAT2; however, INGREZZA demonstrated significantly higher VMAT2 target occupancy and greater potency. Findings were presented at the American College of Neuropsychop
About this update from Neurocrine Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatment","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"VMAT2 occupancy is a key measurement thought to be associated with drug response in involuntary movement disorders, including tardive dyskinesia and Huntington's disease chorea","length":180,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":354,"olType":false},{"type":"text","content":"SAN DIEGO, Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) capsules and AUSTEDO XR (deutetrabenazine) at therapeutic doses. Results from the study confirmed that both compounds engage VMAT2; however, INGREZZA demonstrated significantly higher VMAT2 target occupancy and greater potency. Findings were presented at the American College of Neuropsychopharmacology 64th Annual Meeting taking place January 12-15 in the Bahamas.","length":625,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":74,"url":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/T_HafQLyqDkZ5Jiojrk_IQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","width":400,"height":74}},"href":"https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"VMAT2 inhibition is an established target for treatment of hyperkinetic movement disorders, such as tardive dyskinesia (TD) and Huntington's disease (HD) chorea. VMAT2 target occupancy (TO) is a key measurement thought to be associated with the level of drug response in these conditions. Higher VMAT2 occupancy indicates greater engagement of the target, and inhibition of VMAT2 lowers excessive dopamine transmission associated with inv...